Regulation of Skeletal Muscle Atrophy in Cachexia by MicroRNAs and Long Non-coding RNAs

Skeletal muscle atrophy is a common complication of cachexia, characterized by progressive bodyweight loss and decreased muscle strength, and it significantly increases the risks of morbidity and mortality in the population with atrophy. Numerous complications associated with decreased muscle function can activate catabolism, reduce anabolism, and impair muscle regeneration, leading to muscle wasting. microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), types of non-coding RNAs, are important for regulation of skeletal muscle development. Few studies have specifically identified the roles of miRNAs and lncRNAs in cellular or animal models of muscular atrophy during cachexia, and the pathogenesis of skeletal muscle wasting in cachexia is not entirely understood. To develop potential approaches to improve skeletal muscle mass, strength, and function, a more comprehensive understanding of the known key pathophysiological processes leading to muscular atrophy is needed. In this review, we summarize the known miRNAs, lncRNAs, and corresponding signaling pathways involved in regulating skeletal muscle atrophy in cachexia and other diseases. A comprehensive understanding of the functions and mechanisms of miRNAs and lncRNAs during skeletal muscle wasting in cachexia and other diseases will, therefore, promote therapeutic treatments for muscle atrophy.


INTRODUCTION
Cachexia is a complex metabolic condition accompanied by progressive bodyweight loss, skeletal muscle atrophy, and decreased muscle strength. Muscle atrophy is an important factor associated with physical disability, poor quality of life, and increased mortality (Prado et al., 2008;Fearon et al., 2011). Cachexia is common in patients with certain cancers and other diseases in the advanced stages, such as patients with intensive care unit (ICU)-acquired (Garros et al., 2017) weakness or chronic obstructive pulmonary disease (COPD) (Man et al., 2009), chronic kidney disease (CKD) , and heart failure (Anker et al., 1997). Patients with cachexia are less tolerant or responsive to interventions, which limits the treatment options and their efficacy, for example, the dose-limiting toxicity of radiation and chemotherapy in patients with cancer cachexia (de Castro et al., 2019). Skeletal muscle atrophy in cachexia is due to a disruption in the balance between protein synthesis and degradation, which can be partially, but not fully reversed by nutritional support (Baracos et al., 2018;de Castro et al., 2019). Reduced protein levels result from decreased protein synthesis, increased degradation, and abnormalities in apoptosis or autophagy (Lok, 2015). Protein degradation pathways mainly include ubiquitinproteasome pathway (UPP) and autophagy-lysosomal pathway (ALP). The ubiquitin-proteasome pathway is an active protein degradation pathway that degrades ubiquitinated proteins in cells. This way is mainly composed of ubiquitin, ubiquitin activating enzyme, ubiquitin conjugating enzyme, ubiquitin ligase (ubiquitinprotein ligase, E3), protease and its substrate. E3 specifically regulates target protein degradation by identifying and binding specific target protein sequences. In skeletal muscle, there are two muscle-specific E3 ligases: muscular atrophy fbox-1 protein (MAFbx/Atrogin-1) and muscle-specific RING finger protein -1 (MuRF-1). Atrogin-1 and MuRF-1 are key proteins leading to muscle protein degradation (Rom and Reznick, 2016). Models of muscle atrophy demonstrate a consistent increase in the expression level of Atrogin-1 and MuRF-1. Autophagy is a highly conserved process in eukaryotes that occurs in the cytoplasm, where excess or abnormal organelles are transported to lysosomes for degradation. There are three main types of autophagy in the cell, namely molecular chaperone-mediated autophagy, microautophagy and macrophage. And in our previous study, CoCl 2 -mimicked hypoxia induces autophagy in skeletal C2C12 myotubes, and increases the expression of musclespecific ubiquitin ligase Atrogin-1, which reveals an important link between autophagy and muscle atrophy .
Whereas proteins are thought to be the dominant regulators of cell functions, a variety of non-protein-coding processes also operate. It is increasingly clear that the non-protein-coding parts of the genome are important for development, physiology, and disease progression (Sonkoly et al., 2005;Faghihi et al., 2008). microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are vital non-coding RNAs (ncRNAs). Studies have shown that miRNAs and lncRNAs may be associated with cancer (Ramalho-Carvalho et al., 2017), as well as neurological (Faghihi et al., 2008), cardiovascular (Ponnusamy et al., 2019), and other diseases (Iannone et al., 2020). miRNAs and lncRNAs are also reported to play critical roles in muscle development and other muscle-related diseases, such as skeletal muscle wasting in cachexia (Chen et al., 2006(Chen et al., , 2010. miR-1 (Chen et al., 2006), miR-133 (Chen et al., 2006), miR-206 (Chen et al., 2010, and miR-29b  can modulate muscle development and wasting. Our previous studies showed that 2,922 lncRNAs are differentially regulated during C2C12 differentiation, and these lncRNAs may be involved in multiple mechanisms regulating gene expression (Chen et al., 2018). In recent reports, linc-MD1 was shown to play a vital role through competing endogenous RNA (ceRNA) (Cesana et al., 2011), whereas lincRNA Yam-1 acted in cis , and lncRNA MUNC functioned in trans during skeletal muscle development (Cichewicz et al., 2018). A systematic review of our groups provided a summary of the known functions and mechanisms of lncRNAs in skeletal muscle development . However, 4,409 lncRNAs are differentially regulated by CoCl 2 , which triggers atrophy in skeletal C2C12 myotubes , indicating the potential involvement of lncRNAs in muscle wasting.
To develop approaches to improve skeletal muscle mass, strength, and function, a more comprehensive understanding of the key pathophysiological processes leading to muscular atrophy is needed. Here, we summarize the known miRNAs and lncRNAs regulating skeletal muscle wasting in cachexia and other diseases. A comprehensive understanding of the functions and mechanisms of miRNAs and lncRNAs during muscle atrophy in cachexia will help identify potential therapeutic approaches for muscle atrophy.

miRNAs INVOLVED IN SKELETAL MUSCLE ATROPHY
Although the mechanism of muscular atrophy has been investigated extensively, the key processes driving muscular atrophy in different diseases requires further clarification. miRNAs are short ncRNA molecules (18-25 nucleotides) that are vital negative regulators of gene expression. They fine-tune gene expression via post-transcriptional mechanisms, leading to inhibition of translation or degradation of target mRNAs, and are involved in many biological pathways. miRNAs play important roles in maintaining skeletal muscle homeostasis by regulating muscle metabolism, growth, and regeneration. Muscle-specific miRNAs have emerged as significant regulators of muscle wasting.

miRNAs That Promote Skeletal Muscle Atrophy
Emerging studies have demonstrated that certain miRNAs promote muscle atrophy via the PI3K/Akt/mTOR signaling pathway (Figure 1 and Tables 1, 2). miR-29b promotes atrophy by targeting insulin-like growth factor 1 (IGF-1) and PI3K in response to different atrophic stimuli in cells and mouse models. Inhibition of miR-29b attenuates atrophy induced by dexamethasone (Dex), tumor necrosis factor (TNF)-α, and H 2 O 2 treatment . It was reported that miR-345-5p downregulated nephroblastoma overexpressed (NOV) and upregulated cysteine-rich 61 (Cyr61) in human skeletal muscle with cancer cachexia. NOV and Cyr61 are involved in the IGF-1, Akt, and mTOR pathways which promote protein synthesis, thus miR-345-5p may lead to muscle atrophy by suppressing protein synthesis (Narasimhan et al., 2017). In addition, miR-18a blocks PI3K/Akt signaling by direct inhibition of IGF-1 expression in a 3'UTR-dependent manner in C2C12 myotubes and in mice, and it also decreases the phosphorylation of Akt and FoxO3, thus increases the expression of Atrogin-1, MuRF-1, and cathepsin L, and eventually leads to myotube atrophy .
In addition to the PI3K/Akt/mTOR pathway, two miRNAs can enhance muscle wasting via Akt/FoxO signaling (Figure 1 and Table 1). Increasing miR-1 expression during Dex-induced atrophy reduces the level of HSP70, which can result in  decreased phosphorylation of Akt, enhanced activation of FoxO3, upregulation of Atrogin-1 and MuRF-1, and progression of skeletal muscle atrophy (Kukreti et al., 2013). miR-628 promotes burn-induced skeletal muscle atrophy via targeting insulin receptor substrate 1 (IRS1). Rats subjected to burn injury exhibited skeletal muscle atrophy, significantly decreased IRS1 protein expression, and significantly increased skeletal muscle cell apoptosis. miR-628, a potential regulator of IRS1 protein translation, was also clearly elevated after the burn injury. In experiments in L6 myocytes, apoptosis was accelerated after induction of miR-628 expression, and the protein levels of IRS1 and p-Akt, involved in the IRS1/Akt/FoxO pathway, were decreased significantly. The levels of the apoptosis-related proteins FoxO3 and cleaved caspase 3 were also increased after induction of miR-628 expression (Yu et al., 2016).
Besides the above signaling pathways, some miRNAs facilitate cachexia muscle atrophy by regulating eukaryotic initiation factor 4E (eIF4E), one of the most critical factors regulating ribosome assembly and protein synthesis (Figure 1 and Tables 1, 2). miR-206 enhances wasting by decreasing the action of eIF4E3, and miR-21 inhibits the expression of transcription factor YY1 and eIF4E3, thus promoting muscle wasting in four different models: starvation, denervation, diabetes, and cancer cachexia induced by colon carcinoma (Soares et al., 2014). YY1 is reported to play an important role in the maintenance of mitochondrial functions, and its inactivation may contribute to exercise intolerance and mitochondrial myopathies (Blattler et al., 2012), promoting skeletal muscle wasting. miR-199a-3p affects the eIF4EBP1 gene and reduces the activity of the mTOR pathway, thus interfering with protein synthesis to promote muscle wasting in human skeletal muscle with cancer cachexia (Narasimhan et al., 2017). What's more, in a meta-analysis, miR-199a is identified as a potential miRNA that inhibits Junb and Caveolin 1 expression, thus suppressing muscle wasting in cancer cachexia (Freire et al., 2019).
Additionally, miRNAs may contribute to muscle wasting via other pathways (Figure 1 and Tables 1, 2). Elevated miR-542-5p may cause muscle atrophy in ICU patients by activating SMAD2/3 phosphorylation. miR-542-5p increases the p-SMAD2/3 level by suppressing the inhibitory components of the TGF-β signaling pathway via a reduction in the expression of SMAD7 and SMURF1, inhibitors of TGF-β type I receptors, and by reducing the phosphatases (such as PPP2CA) that limit TGF-β signaling by dephosphorylating and inactivating SMADs (Garros et al., 2017). In other research, miR-542-3p suppressed ribosomal protein S23 expression and maximal protein synthesis in vitro. In COPD patients, miR-542-3p expression in quadriceps was elevated, and this may suppress physical performance, at least in part, by inhibiting mitochondrial and cytoplasmic ribosome synthesis and suppressing protein synthesis, leading to speculation that miR-542-3p may promote wasting (Farre- Garros et al., 2019). Also, miR-424-5p regulates rRNA synthesis by inhibiting Pol I pre-initiation complex formation, which reduces the capacity of the protein synthesis machinery, contributing to inhibition of protein synthesis and loss of muscle mass in patients with ICU-acquired weakness or COPD, patients undergoing aortic surgery, and in individuals from the Hertfordshire Sarcopenia Study . miR-424-5p expression is elevated in muscle of cachectic non-small cell lung cancer (NSCLC) patients compared with healthy control subjects; however, the mechanism underlying the altered expression of miR-424-5p in NSCLC muscle atrophy is unknown (Worp et al., 2020). miR-142a-5p can inhibit mitofusin-1 (MFN1) expression by binding to the 3'UTR of its mRNA. Following overexpression of miR-142a-5p in C2C12 cells and a sciatic nerve transaction mouse model, MFN1 was downregulated, associated with extensive mitochondrial fragmentation, depolarization of mitochondrial membrane potential, accumulation of reactive oxygen species (ROS), and mitophagy and apoptosis activation in skeletal muscle cells, all of which aggravate muscle atrophy. Importantly, these effects were attenuated by overexpression of MFN1 .

miRNAs That Attenuate Muscle Atrophy
Research strategies based on multiple muscular atrophy models and patient-derived muscle biopsies have also been applied to identify the miRNAs involved in decreasing muscle atrophy in cachexia. These studies have confirmed the crucial roles of miRNAs in regulating muscle wasting in cachexia, and miRNAs in different models of muscle wasting in cachexia can repress wasting via a variety of mechanisms.
Phosphatase and tensin homolog (PTEN), originally identified as a tumor suppressor, also plays a significant role in skeletal muscle atrophy (Wijesekara et al., 2005;Hu et al., 2007Hu et al., , 2010. It was reported that miRNAs attenuate muscle wasting of cachexia via PTEN/PI3K/Akt signaling (Figure 2 and Table 3). miR-486 and miR-26a repressed the translation of PTEN in a model of CKD, resulting in enhanced phosphorylation of Akt and FoxO1; miR-486 and miR-26a also directly inhibit the translation of FoxO1, and both of these effects lead to suppression of Atrogin-1 and MuRF-1 to prevent muscle atrophy (Small et al., 2010;Xu et al., 2012;. miR-182 has also been reported to target FoxO. In muscle cells, miR-182 reduces FoxO3 expression and also blocks glucocorticoid-induced upregulation of multiple FoxO3 targets, including Atrogin-1, autophagyrelated protein 12, cathepsin L, and microtubule-associated protein light chain 3, to decrease muscle wasting. miR-182 expression is decreased in C2C12 myotubes with Dex-induced muscle atrophy and in the gastrocnemius muscle of rats injected with streptozotocin-induced diabetes-related atrophy (Hudson et al., 2014a).
Overexpression of miR-23a/miR-27a in CKD mice enhanced grip strength, decreased muscle loss, increased the phosphorylation of Akt and FoxO1, decreased the activation of PTEN and FoxO1, and reduced Atrogin-1 and MuRF-1 protein levels, preventing muscle wasting via PTEN/PI3K/Akt signaling . These results are consistent with those of a streptozotocin-induced diabetic muscle atrophy model, and administration of miR-23a/27a weakened the diabetes-induced decrease in the muscle cross-sectional area and muscle function . PTEN and caspase-7 are targets of miR-23a, and FoxO1 is a target of miR-27a, as identified by luciferase reporter assays in primary satellite cells . In a meta-analysis, miR-27a was showed as a new potential FoxO1 regulator during muscle wasting in cancer cachexia; miR-27a inhibits the expression of FoxO1, so as to inhibit muscle atrophy (Freire et al., 2019).
miR-23a/27a also participates in the myostatin or TGFβ/SMAD signaling pathways to decrease muscle atrophy, similar to other miRNAs, such as miR-29, miR-422a, and miR-206 (Figure 2 and Tables 2, 3). Administration of miR-23a/miR-27a also reduces myostatin expression and its downstream SMAD 2/3 signaling, diminishes caspase 3/7 activation, and increases the expression of muscle regeneration markers . In unilateral ureteral obstruction-induced  muscle atrophy, miR-29 ameliorates atrophy and weakens renal fibrosis by suppressing the YY1 and TGF-β signaling proteins directly. YY1 inhibits muscle satellite cell proliferation, leading to the development of muscle wasting . In male patients with ICU-associated muscle weakness or COPD or who were undergoing aortic surgery, quadriceps expression of miR-422a was positively associated with muscle strength. In muscle cells in vitro, miR-422a targeted and restrained SMAD4 expression, a central component of the canonical TGF-β signaling pathway, and suppressed the luciferase activity induced by TGFβ and bone morphogenetic protein (Bmp). In addition, the preoperative miR-422a level is inversely correlated with muscle mass loss during the first week after surgery . In a recent study, basic muscle characteristics, such as relative muscle weight, deteriorated continually during a 2-week period after surgical transection of the sciatic nerve. Injection of miR-206 attenuated the deterioration of muscle morphology and physiology, effectively blocked fibrosis, and suppressed TGF-β1 and HDAC4 expression as evaluated at 2 weeks after denervation. Moreover, miR-206 treatment increased the number of differentiating satellite cells, thereby protecting the denervated muscles from atrophy. Interestingly, the ability of miR-206 to regulate HDAC4 expression and to decrease muscle atrophy weakened after pharmacological blockade of the TGF-β/SMAD3 axis (Huang et al., 2016), suggesting that miR-206 may attenuate muscle atrophy via the TGF-β/SMAD3 axis. Other research on miR-206 showed that miR-206 targeted and inhibited HDAC4, and overexpression or inhibition of miR-206 in the muscles of mice reduced or increased HDAC4 levels, respectively, but did not alter muscle mass or myofiber size. Vectormediated manipulation of miR-206 activity in follistatin-induced hypertrophy and denervation-induced atrophy models did not alter the gain and loss of muscle mass, respectively; miR-206 repressed the hypertrophy of myogenic cells, but not muscle fibers via inhibition of HDAC4 (Winbanks et al., 2013). These two studies showing that miR-206 decreased muscle atrophy are in contrast to another study reporting that miR-206 promotes wasting (Soares et al., 2014). HDAC4 is also targeted by miR-29c, which decreases muscle atrophy .
In addition to targeting HDAC4, miR-29c may reduce muscle wasting via other pathways (Figure 2 and Table 3). miR-29c can bind to the 3'UTR of MuRF-1 to inhibit its expression. miR-29c is reported to improve skeletal muscle size and function by stimulating satellite cell proliferation and suppressing atrophyrelated genes. Overexpression of miR-29c inhibits the expression of Atrogin-1, MuRF-1, and HDAC4 . miR-23a can also inhibit the translation of both Atrogin-1 and MuRF-1 in a 3'UTR-dependent manner. Ectopic expression of miR-23a is sufficient to protect muscles from Dex-induced atrophy in vitro and in vivo (Wada et al., 2011). In another study, miR-23a was decreased in the gastrocnemius of rats with acute streptozotocin-induced diabetes, a condition known to increase the expression of Atrogin-1 and MuRF-1 and to cause atrophy; miR-23a also reduced in a Dex-induced atrophy model of C2C12 myotubes. The two atrophy-inducing conditions downregulated miR-23a in muscles by mechanisms involving attenuation of the calcineurin/nuclear factor of activated T cells signaling pathway (Hudson et al., 2014b). miR-351 can inhibit denervation-induced atrophy of tibialis anterior (TA) muscles following sciatic nerve transection, at least partially, via negative regulation of tumor necrosis factor receptor-associated factor 6 (TRAF6), as well as Atrogin-1 and MuRF-1, two signaling molecules downstream of TRAF6 (He et al., 2016). This is consistent with the results of the Dex-induced myotube atrophy model (Qiu et al., 2018). TRAF6 is also directly targeted by miR-125b-5p. The expression of miR-125b-5p is downregulated in both atrophic fasting C2C12 myotubes and denervated TA muscles (Qiu et al., 2019), and our research showed that several miRNAs were downregulated under atrophic fasting/starvation conditions in C2C12 myotubes or mice . Overexpression of miR-125b-5p protects skeletal muscle samples by targeting TRAF6 via downregulation of Atrogin-1, MuRF-1, and autophagy-lysosome system-related proteins (Qiu et al., 2019).
These data validate the roles of miRNAs in mediating the effects of anabolic and catabolic factors. Especially, experimentally manipulated miRNA expression can attenuate or even reverse skeletal muscle atrophy during cachexia and other diseases, suggesting the substantial contribution of miRNAs in regulating skeletal muscle mass and functions in muscle wasting.

lncRNAs INVOLVED IN SKELETAL MUSCLE ATROPHY
lncRNAs are ncRNAs longer than 200 nucleotides. A small group of lncRNAs are reportedly expressed in muscle, and they have emerged as significant regulators that promote or attenuate muscle atrophy in cachexia and other diseases (Figure 3 and Table 4). These lncRNAs include the lncRNAs Chronos, atrophy-related long non-coding RNA-1 (Atrolnc-1), mechanical unloading-induced muscle atrophy-related lncRNA (lncMUMA), and lncIRS1 (TCONS-00086268). Studies on the regulation of muscle atrophy in cachexia by lncRNAs are just in the infant stage, the descriptions of lncRNA Pvt1 and SMN-AS1 in other diseases is helpful to a more comprehensive understanding of the relationship between lncRNA and muscle atrophy.
lncRNA Chronos (lncRNA Gm17281), located on chromosome 2, is a muscle-enriched, aging-related lncRNA that is inhibited by Akt and serves as an inhibitor of hypertrophic growth (Neppl et al., 2017), suggesting that Chronos may lead to muscular wasting by restraining hypertrophic growth. Chronos, however, does not appear to function as a classical 'atrogene' because its expression is uncoupled from the loss of muscle mass in atrophy models of aging, hind limb unloading, and streptozotocin-induced type 1 diabetes mice. Chronos is negatively regulated by Akt signaling and positively regulated by aging. Chronos can repress hypertrophic growth in vitro and in vivo, in part, by in trans negatively regulating Bmp7 expression, which is located on chromosome 20 (Neppl et al., 2017). This is consistent with prior studies reporting hypertrophic effects of Bmp signaling, which has been shown to positively regulate skeletal muscle hypertrophy via activation of SMAD1/5/8 (Sartori et al., 2013).
Atrolnc-1 increases muscle wasting in fasting mice and mice with cancer, or chronic kidney disease (CKD). Reduced insulin signaling promotes the binding of the transcription factor C/EBPα to the Atrolnc-1 promoter and increases Atrolnc-1 expression. In cultured C2C12 myotubes, overexpression of Atrolnc-1 promotes protein degradation, whereas Atrolnc-1 knockdown significantly decreases the protein degradation rate increased by serum depletion. Atrolnc-1 interacts with A20 binding inhibitor of NF-κB-1 to inhibit its function, leading to heightened NF-κB activity and MuRF-1 transcription. In the TA muscle of normal mice, overexpression of Atrolnc-1 increases MuRF-1 expression, which results in a loss of myofibers. Knockdown of Atrolnc-1 reduced muscle atrophy in mice with CKD by inhibiting NF-κB activity and MuRF-1 expression (Sun et al., 2018).
In addition to increasing muscle wasting, lncRNAs have also been reported to attenuate muscle atrophy. Mechanical unloading-induced muscle atrophy-related lncRNA (lncMUMA), which is enriched in muscles, can reverse the muscle atrophy induced by hindlimb suspension. lncMUMA is the most downregulated lncRNA during muscle wasting FIGURE 3 | lncRNA-mediated networks regulating skeletal muscle atrophy in cachexia and other diseases. The lncRNAs are represented in red; miRNAs or proteins directly targeted by lncRNAs are shown in blue or pink, respectively; the molecules regulated downstream of miRNAs or proteins interacting with lncRNAs are shown in orange; and other signaling molecules involved in muscle wasting are shown in purple. Spinal muscular atrophy mice Woo et al., 2017 induced by hindlimb suspension mice. In vitro and in vivo data show that the reduction in lncMUMA is closely related to decreased myogenesis during mechanical unloading. In vitro, lncMUMA functions as a miR-762 sponge and facilitates myogenic differentiation by modulating MyoD. Overexpression of lncMUMA alleviates the loss of MyoD protein and muscle mass in miR-762 knock-in mice. In microgravity simulation, overexpression of lncMUMA can accelerate the myogenic differentiation of myoblasts and block the development of muscle wasting in vitro (Zhang et al., 2018a). lncIRS1 can regulate the expression of atrophy-related genes and rescue muscle wasting. lncIRS1 is particularly enriched in skeletal muscle. lncIRS1 can regulate proliferation and differentiation of myoblasts in vitro and the mass and crosssectional area of muscle fibers in vivo. The expression of lncIRS1 gradually increases with myogenic differentiation. lncIRS1 can act as a ceRNA for miR-15a, miR-15b-5p, and miR-15c-5p to modulate the expression of IRS1, which is downstream of the IGF-1 receptor. Overexpression of lncIRS1 accelerates the protein expression of IRS1 and facilitates p-Akt signaling, which is a core component of the IGF-1 signaling pathway, leading to the promotion, proliferation, and differentiation of myoblasts and the rescue of muscle atrophy .
Single cell analysis showed that the lncRNA Pvt1, which is activated in early muscle wasting, is involved in promoting muscle atrophy and modulating the mitochondrial network. Pvt1 silencing in models of denervation and amyotrophic lateral sclerosis atrophy resulted in a less fragmented mitochondrial network compared with the controls (Alessio et al., 2019). Pvt1 can prevent c-Myc degradation by hindering phosphorylation of Thr58 in c-Myc (Johnsson and Morris, 2014). c-Myc inhibits the anti-apoptotic protein Bcl-2 (Eischen et al., 2001), which is a key promoter of apoptosis and autophagy, two vital events that occur during muscle atrophy. Bcl-2 can inhibit Beclin 1 and Bax, which enhance autophagy and apoptosis, respectively, leading to muscle wasting (Alessio et al., 2019).
lncRNAs, such as SMN-AS1, also play important roles in accelerating muscle atrophy in SMA. lncRNA SMN-AS1 is transcribed from the antisense strand of the SMN gene and is highly enriched in neurons (D Ydewalle et al., 2017). SMN-AS1 increases muscle wasting by recruiting polycomb repressive complex 2 (PRC2) to the SMN promoter and restricting SMN transcription (Woo et al., 2017). In addition, selective destruction of SMN-AS1-mediated PRC2 recruitment results in activated SMN, attenuated muscle atrophy, and improved SMA phenotypes in mice (Woo et al., 2017).
Recently, several studies have demonstrated the crucial roles of lncRNAs in regulating skeletal muscle atrophy. lncRNAs have been identified as metabolic regulators promoting or reversing muscle atrophy in a variety of wasting models; however, our comprehension of the biological functions of lncRNAs in wasting is still in its infancy. Knowledge of the mechanisms of lncRNA regulation of muscle atrophy may aid the development of potential therapeutics for the clinical treatment of muscle atrophy in cachexia and other diseases.

CONCLUSION AND PERSPECTIVES
Skeletal muscle, which can contract or stretch, is vital for body metabolism, homeostasis, and movement (Agudelo et al., 2019;Amoasii et al., 2019;Fiorenza et al., 2019). The development of skeletal muscle has been studied in depth, and a variety of regulatory molecules and complex mechanisms are involved in skeletal muscle development. However, when the normal development of skeletal muscle is disrupted, pathological conditions develop.
Skeletal muscle atrophy in cachexia is due to disruption of the balance between protein synthesis and degradation, which can be partially, but not entirely, reversed by nutritional support (Baracos et al., 2018;de Castro et al., 2019). Weight loss is a significant feature of cachexia and is closely associated with mortality (de Castro et al., 2019). Cachexia is very common in cancer patients, with up to 80% of patients having advancedstage disease (Porporato, 2016), and cachexia is the immediate cause of death in at least 20% of all cancer patients (Porporato, 2016). Interventions to block or attenuate muscle wasting, while preventing the progression of cachexia, are highly desirable.
The discovery of ncRNAs has opened up a new chapter in medicine (Adams et al., 2017;Rupaimoole and Slack, 2017;Levin, 2019), of which we have just begun to scratch the surface. Focusing on disease-specific and tissue-specific ncRNAs seems to be an ideal approach to identify candidate biomarkers or therapeutic targets, for example, lncRNA PCA3 (also known as DD3) in prostate cancer (Hessels et al., 2003;Tomlins et al., 2011Tomlins et al., , 2016Mitra et al., 2020). lncRNA PCA3 is the first ncRNA to receive Food and Drug Administration approval as a cancer biomarker test (Hessels et al., 2003). Although therapeutic applications are still in their infancy, drugs targeting ncRNAs that participate in cancer signaling will hopefully be used to treat cancer patients one day.
In addition to the regulations and potential applications of ncRNAs in cancers, increasing research on the functions of ncRNAs in skeletal muscle suggests that miRNAs and lncRNAs are significant regulators of muscular atrophy in cachexia and other diseases (Crone et al., 2012;Alexander et al., 2014;Narasimhan et al., 2017;Cao et al., 2018;Okugawa et al., 2018;Mitra et al., 2020;Shuai et al., 2020). The roles of miRNAs in skeletal muscle in certain diseases have been well described in different muscular atrophy models, and in recent years, the involvement of miRNAs in regulating muscular atrophy in cachexia has been confirmed. These miRNAs could serve not only as biomarkers for muscle status and wasting but also as biomarkers to monitor muscle regeneration and therapy effects (Suzuki and Springer, 2018). miRNAs associated with muscular atrophy in disease are expected to be identified in the future, and they may function by many different mechanisms. In addition, lncRNAs are reported to participate in various physiological and pathological processes, such as cancer He et al., 2014;Sun et al., 2014;Zhuang et al., 2014;Yin et al., 2015;Zhou et al., 2015;Zou et al., 2016;Wang J. et al., 2017), aging (Boon et al., 2016;Su et al., 2019), muscle development (Ballarino et al., 2018;Jin et al., 2018;Zhang et al., 2018b), and their associated disorders (Han et al., 2020). A better understanding of the roles of miRNAs and lncRNAs and their corresponding signaling pathways in regulating skeletal muscle atrophy in cachexia and other diseases will eventually help elucidate the mechanisms underlying muscle wasting and may contribute to the design of new strategies for the prevention, diagnosis, and treatment of muscle-wasting diseases.
In summary, there have been significant advances in our understanding of the crucial roles of miRNAs and lncRNAs in regulating skeletal muscle development (Cesana et al., 2011;Legnini et al., 2014;Zhu et al., 2017;Kong et al., 2019;Cheng et al., 2020;Li et al., 2020). A limited number of studies have specifically identified roles of miRNAs and lncRNAs in muscular atrophy in cachexia and other diseases, and these studies suggest that miRNAs and lncRNAs are central to abnormal regulation of protein synthesis and degradation. Moreover, preliminary evidence suggests that miRNAs and lncRNAs are involved in muscle-organ crosstalk that leads to muscle disorder in COPD , CKD Zhang et al., 2019), and heart failure (Kumarswamy et al., 2014;Santer et al., 2019). The roles of altered miRNA (such as miR-29b) and lncRNA levels warrant further investigation in muscle wasting and cachexia (Bei and Xiao, 2017). This phenomenon may hold great potential for the development of possible strategies to treat muscle, pulmonary, kidney, and heart diseases contemporaneously. The challenge is how to use these miRNAs and lncRNAs to develop more effective, economic, preventive, diagnostic, and therapeutic tools to improve the quality of life and decrease the mortality of patients with muscular atrophy in cachexia and other diseases.

AUTHOR CONTRIBUTIONS
RC conceived the study. RC and SL drafted and revised the manuscript. TJ, YS, and HS performed the literature search and contributed to the draft. All authors read and approved the final version.